Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Izzy who wrote (2451)	10/22/1997 1:39:00 AM
From: JOHN W.	Read Replies (1) of 6136

More from L. Moss today on European sales: Subject: Viracept revenues now exceed Merck's Crixivan's in U.S. market Date: Tue, Oct 21, 1997 14:42 EDT From: LMoss Message-id: <19971021184201.OAA02765@ladder02.news.aol.com> In the third calendar quarter of this year (quarter just ended), Merck's Crixivan had revenues of $71 million in the U.S. This compares with the $75 million achieved by Agouron's Viracept. Viracept U.S. revenues have increased by $31 million in each of the last two quarters. I think it will do a bit better in the current quarter (a $35 million increase), which is why I previously estimated 3QFY98 at $110 million. When Viracept is approved in Europe and elsewhere, there is no reason to believe that it will not soon (within six to nine months) pull ahead of Crixivan in those markets as well. LMoss

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next